These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 23347954

  • 1. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
    Wang HL, Hu SH, Chou AH, Wang SS, Weng YH, Yeh TH.
    Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
    [Abstract] [Full Text] [Related]

  • 2. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
    Chou AH, Chen YL, Chiu CC, Yuan SJ, Weng YH, Yeh TH, Lin YL, Fang JM, Wang HL.
    Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
    Chou AH, Chen SY, Yeh TH, Weng YH, Wang HL.
    Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
    Hübener J, Riess O.
    Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
    [Abstract] [Full Text] [Related]

  • 8. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J, Weber JJ, Richter C, Honold L, Weiss A, Murad F, Breuer P, Wüllner U, Bellstedt P, Paquet-Durand F, Takano J, Saido TC, Riess O, Nguyen HP.
    Hum Mol Genet; 2013 Feb 01; 22(3):508-18. PubMed ID: 23100324
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL.
    Chou AH, Yeh TH, Kuo YL, Kao YC, Jou MJ, Hsu CY, Tsai SR, Kakizuka A, Wang HL.
    Neurobiol Dis; 2006 Feb 01; 21(2):333-45. PubMed ID: 16112867
    [Abstract] [Full Text] [Related]

  • 12. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H, Tang J, Hu Z, Tan J, Tang B, Jiang Z.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb 01; 27(1):23-8. PubMed ID: 20140862
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM.
    Neurobiol Dis; 2013 Oct 01; 58():49-56. PubMed ID: 23659897
    [Abstract] [Full Text] [Related]

  • 16. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells.
    Konno A, Shuvaev AN, Miyake N, Miyake K, Iizuka A, Matsuura S, Huda F, Nakamura K, Yanagi S, Shimada T, Hirai H.
    Cerebellum; 2014 Feb 01; 13(1):29-41. PubMed ID: 23955261
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice.
    Garden GA, Libby RT, Fu YH, Kinoshita Y, Huang J, Possin DE, Smith AC, Martinez RA, Fine GC, Grote SK, Ware CB, Einum DD, Morrison RS, Ptacek LJ, Sopher BL, La Spada AR.
    J Neurosci; 2002 Jun 15; 22(12):4897-905. PubMed ID: 12077187
    [Abstract] [Full Text] [Related]

  • 19. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
    Nguyen HP, Hübener J, Weber JJ, Grueninger S, Riess O, Weiss A.
    PLoS One; 2013 Jun 15; 8(4):e62043. PubMed ID: 23626768
    [Abstract] [Full Text] [Related]

  • 20. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
    Rüb U, de Vos RA, Brunt ER, Sebestény T, Schöls L, Auburger G, Bohl J, Ghebremedhin E, Gierga K, Seidel K, den Dunnen W, Heinsen H, Paulson H, Deller T.
    Brain Pathol; 2006 Jul 15; 16(3):218-27. PubMed ID: 16911479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.